ASCO 2015: Results of the ELOQUENT-2 trial of elotuzumab in multiple myeloma

At ASCO 2015, Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide plus dexamethasone with or without elotuzumab in patients with relapsed or ... Author: VJHemOnc Added: 07/10/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts